Clik here to view.
IASO Biotherapeutics Publishes Preclinical Results of Its CD5-Targeting CAR-T...
PLEASANTON, Calif. & NANJING, China & SHANGHAI IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company advancing the development of novel cell therapies for cancer, today...
View ArticleClik here to view.
Guided Therapeutics Receives Notification of Successful Clinical Trial...
PEACHTREE CORNERS, Ga. Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva® Advanced Cervical Scan, based on its patented biophotonic technology, announced today it had passed the...
View ArticleClik here to view.
BeiGene Announces Acceptance of a Supplemental Biologics License Application...
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced...
View ArticleClik here to view.
ゾールとワラビー・メディカルが中国における温度管理製品の販売契約を発表
米マサチューセッツ州チェルムズフォード （ビジネスワイヤ） — 旭化成傘下で医療機器と関連ソフトウエアソリューションを製造するゾール・メディカル・コーポレーションと、脳卒中と心停止の治療に専心する医療機器企業のワラビー・メディカル・テクノロジーズは本日、販売契約を締結し、ワラビーが中国におけるゾールの温度管理製品の販売・流通を運営すると発表しました。...
View ArticleClik here to view.
ZOLL和Wallaby Medical宣布达成在中国分销体温管理产品的协议
马萨诸塞州切尔姆斯福德 (美国商业资讯)–旭化成(Asahi Kasei)旗下主营医疗器械制造和相关软件解决方案的ZOLL® Medical Corporation和致力于治疗卒中和心脏骤停的医疗器械公司Wallaby Medical Technologies今天宣布，双方已签署分销协议，Wallaby将负责在中国销售和分销ZOLL的体温管理产品。...
View ArticleClik here to view.
FDA、世界最小の心臓ポンプImpella ECPを画期的医療機器に指定
米マサチューセッツ州ダンバース （ビジネスワイヤ） — 米国食品医薬品局（FDA）は、アビオメッド（NASDAQ: ABMD）の拡張型経皮的心臓ポンプImpella ECPを画期的医療機器に指定しました。この指定は、FDAが設計反復、臨床試験プロトコル、市販前承認（PMA）の申請を含むImpella ECPの規制当局の審査プロセスを優先することを意味します。...
View ArticleClik here to view.
Oclean Launches Oclean W10 Water Flosser, Expanding Usage Scenarios to...
NEW YORK This week, Oclean, the pioneer of the Smart Oral & Dental Care industry, is launching a stylish and compact water flosser – Oclean W10 with more flexibility, portability, and stability....
View ArticleClik here to view.
Applications of Bioluminescent Research Tools Showcased at Global Seminar Series
MADISON, Wis. Life science and drug discovery researchers interested in bioluminescent tools will have the opportunity to hear from global thought leaders on the possibilities and applications of...
View ArticleClik here to view.
Cerba Research and ACT Genomics Announce Strategic Joint Venture — CerbACT Asia
GHENT, Belgium Cerba Research, a leading global clinical trial laboratory services organization owned by Cerba HealthCare, announced today that they have joined forces with ACT Genomics under a...
View ArticleClik here to view.
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial...
PALO ALTO, Calif. & SHANGHAI & PRINCETON, N.J. LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and...
View ArticleClik here to view.
BridgeBio与联拓生物宣布，Infiglatinib在用于胃癌及其他晚期实体瘤的2a期临床试验中完成中国首例患者给药
帕罗奥图（美国加利福尼亚州）、上海和普林斯顿（美国新泽西州） (美国商业资讯)–联拓生物，一家专注于为中国和亚洲主要市场的患者带来颠覆性药物的生物制药公司，与BridgeBio Pharma股份有限公司（纳斯达克交易代码：BBIO）今日宣布，infigratinib...
View ArticleClik here to view.
Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19...
SYDNEY Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil...
View ArticleClik here to view.
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for...
ALAMEDA, Calif. Exelixis, Inc. (Nasdaq: EXEL) today announced Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX®...
View ArticleClik here to view.
RubrYc Therapeutics宣布与iBio, Inc.达成A2轮优先股权融资、合作协议及RTX-003许可
加州圣卡洛斯 (美国商业资讯)–RubrYc Therapeutics, Inc. (“RubrYc”)和iBio, Inc. (“iBio”, NYSEA: IBIO)今天宣布完成RubrYc的A2轮优先股融资，以及针对表位靶向抗体疗法研发和商业化的伴随许可和合作协议。通过本次交易，iBio凭借其对RubrYc的A2轮优先股权的750万美元投资成为该公司重要战略投资者，加入由Third...
View ArticleClik here to view.
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has received two new approvals from the Japan...
View ArticleClik here to view.
Noxopharm的I期临床试验显示新冠肺炎患者有抗炎应答
悉尼 (美国商业资讯)–澳大利亚临床阶段药物开发公司Noxopharm (ASX:NOX)已发布其NOXCOVID I期临床试验的初步头条数据，该试验旨在研究TBK1（TANK结合激酶1）抑制剂idronoxil...
View ArticleClik here to view.
Clik here to view.
Noxopharm Preclinical Data Further Supports Anti-Inflammatory Role of...
SYDNEY Australian clinical-stage drug development company Noxopharm (ASX:NOX) has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active...
View ArticleClik here to view.
ルーブリック・セラピューティクスがシリーズA2の優先株式資金調達、iBioとの提携およびRTX-003のライセンス供与を発表
米カリフォルニア州サンカルロス （ビジネスワイヤ） — ルーブリック・セラピューティクス(「ルーブリック」)とiBio（アイバイオ） (「iBio」、NYSEA:...
View ArticleClik here to view.
ゾール・メディカル・コーポレーションがItamar Medicalを買収する正式契約に署名
米マサチューセッツ州チェルムスフォード & イスラエル・カイサリア （ビジネスワイヤ） — 医療機器と関係ソフトウエアソリューションを製造する旭化成傘下のゾール・メディカル・コーポレーションと、睡眠時無呼吸診断の心臓病患者ケアへの組み込みに注力する医療機器・デジタルヘルス企業のItamar™ Medical...
View Article